Harnessing the Power of Patient Organisations: A Case Study of PO-Driven Drug Development in Ultra-Rare Disease

How can patient organisations and pharmaceutical companies collaborate effectively to develop treatments for rare and ultra-rare diseases? In this white paper, we analyse the benefits and pitfalls of co-operation between patient organisations and pharma.

A case study illustrates how a pragmatic and respectful approach can lead to successful outcomes for both parties and that patient organisations can be powerful drivers of drug development.

For pharma companies, seeking out collaborations with patient organisations is an advisable approach but requires careful and consistent management to succeed. We highlight the challenges, opportunities, and best practices involved.

Download the white paper to review the recommendations for creating a successful collaboration between patient organisations and pharma.

Patient Associations

Accelerate the development of new therapies.

Government

Use big data and predictive analytics to improve human health.

Patient Engagement Suite

Technology informed by unparalleled Decentralized Trials (DCT) operational experience and delivered at global scale.

Rare Diseases

Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.

Get instant access

Related solutions